{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:54:18Z","timestamp":1783515258144,"version":"3.55.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003121","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:30:26Z","timestamp":1594920626000},"page":"e1003121","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":94,"title":["Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":true,"given":"Arrigo F. G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":true,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":true,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"pmed.1003121.ref001","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"D Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"pmed.1003121.ref002","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"BA Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"pmed.1003121.ref003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14740338.2019.1620730","article-title":"Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.","volume":"18","author":"L Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"pmed.1003121.ref004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","article-title":"ETC-1002 (bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.","volume":"20","author":"M Ruscica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"pmed.1003121.ref005","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1074\/jbc.M310512200","article-title":"ATP-citrate lyase deficiency in the mouse","volume":"279","author":"AP Beigneux","year":"2004","journal-title":"J Biol Chem"},{"key":"pmed.1003121.ref006","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","article-title":"The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2.","volume":"272","author":"TA Berkhout","year":"1990","journal-title":"Biochem J"},{"key":"pmed.1003121.ref007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccl.2017.12.007","article-title":"Bempedoic acid (ETC-1002): a current review.","volume":"36","author":"A Saeed","year":"2018","journal-title":"Cardiol Clin."},{"key":"pmed.1003121.ref008","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"SL Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"pmed.1003121.ref009","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"U Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"pmed.1003121.ref010","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"PRISMA Group","year":"2009","journal-title":"BMJ"},{"key":"pmed.1003121.ref011","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2008"},{"key":"pmed.1003121.ref012","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1080\/10408398.2017.1332572","article-title":"Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis.","volume":"58","author":"A Sahebkar","year":"2018","journal-title":"Crit Rev Food Sci Nutr"},{"key":"pmed.1003121.ref013","volume-title":"Comprehensive meta-analysis. Version 3","author":"M Borenstein","year":"2013"},{"key":"pmed.1003121.ref014","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response.","volume":"45","author":"D Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"pmed.1003121.ref015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"X Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"pmed.1003121.ref016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"WG Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"pmed.1003121.ref017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0021-9681(56)90049-2","article-title":"Statistical approaches to the study of cancer with particular reference to case registers","volume":"4","author":"W Haenszel","year":"1956","journal-title":"J Chronic Dis"},{"key":"pmed.1003121.ref018","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/dom.13324","article-title":"Resveratrol effect on patients with non-alcoholic fatty liver disease: a matter of dose and treatment length","volume":"20","author":"F Fogacci","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003121.ref019","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.2174\/0929867323666161007155310","article-title":"A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine levels","volume":"23","author":"A Sahebkar","year":"2016","journal-title":"Curr Med Chem"},{"key":"pmed.1003121.ref020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel\u2010plot\u2013based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"S Duval","year":"2000","journal-title":"Biometrics"},{"key":"pmed.1003121.ref021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"CM Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"pmed.1003121.ref022","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial.","volume":"13","author":"ND Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"pmed.1003121.ref023","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"KK Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"pmed.1003121.ref024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"CM Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"pmed.1003121.ref025","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy.","volume":"117","author":"CM Ballantyne","year":"2016","journal-title":"Am J Cardiol."},{"key":"pmed.1003121.ref026","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.","volume":"10","author":"PD Thompson","year":"2016","journal-title":"J Clin Lipidol."},{"key":"pmed.1003121.ref027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"MJ Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pmed.1003121.ref028","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.","volume":"9","author":"PD Thompson","year":"2015","journal-title":"J Clin Lipidol."},{"key":"pmed.1003121.ref029","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","article-title":"Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial","volume":"62","author":"CM Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"pmed.1003121.ref030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"pmed.1003121.ref031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","author":"AK Gitt","year":"2016","journal-title":"Atherosclerosis"},{"issue":"18","key":"pmed.1003121.ref032","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1177\/2047487318806359","article-title":"Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.","volume":"25","author":"J Ferrieres","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"pmed.1003121.ref033","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","article-title":"Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis","volume":"28","author":"M Lemstra","year":"2012","journal-title":"Can J Cardiol"},{"key":"pmed.1003121.ref034","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.","volume":"7","author":"MY Wei","year":"2013","journal-title":"J Clin Lipidol."},{"key":"pmed.1003121.ref035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","article-title":"Statin-associated muscle disease: advances in diagnosis and management.","volume":"15","author":"BA Taylor","year":"2018","journal-title":"Neurotherapeutics"},{"key":"pmed.1003121.ref036","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment. Aetiology and management","volume":"36","author":"ES Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"pmed.1003121.ref037","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"N Sattar","year":"2010","journal-title":"Lancet"},{"key":"pmed.1003121.ref038","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"SF Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"pmed.1003121.ref039","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"CP Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"pmed.1003121.ref040","first-page":"CD012502","article-title":"Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.","volume":"11","author":"S Zhan","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"pmed.1003121.ref041","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2459\/JCM.0000000000000680","article-title":"Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II\u2014Italy.","volume":"19","author":"GM De Ferrari","year":"2018","journal-title":"J Cardiovasc Med"},{"key":"pmed.1003121.ref042","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"10","author":"D Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"pmed.1003121.ref043","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14656566.2019.1604687","article-title":"Current pharmacotherapeutic options for primary dyslipidemia in adults.","volume":"20","author":"AFG Cicero","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"pmed.1003121.ref044","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"4","key":"pmed.1003121.ref045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4158\/EP171764.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease\u2014executive summary","volume":"23","author":"PS Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"pmed.1003121.ref046","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14712598.2017.1341485","article-title":"Emerging biologic therapies for hypercholesterolaemia.","volume":"17","author":"G Pucci","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"pmed.1003121.ref047","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5603\/KP.a2019.0013","article-title":"Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials.","volume":"77","author":"X Wang","year":"2019","journal-title":"Kardiol Pol."},{"issue":"9","key":"pmed.1003121.ref048","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17460441.2019.1615436","article-title":"Can we further optimize statin therapy to increase tolerability?","volume":"14","author":"M Ruscica","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"pmed.1003121.ref049","unstructured":"Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). NCT02993406. ClinicalTrials.gov. 2016 Dec 15 [cited 2020 Jun 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:30:52Z","timestamp":1594920652000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003121"}},"subtitle":[],"editor":[{"given":"Anthony","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003121","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}